ATR
Serine/threonine-protein kinase ATR
Also known as: ATR_HUMAN, FRP1, MEC1, SCKL, SCKL1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q13535
- Gene
- ATR
- Ensembl
- ENSG00000175054
- Chromosome
- 3
- Canonical length
- 2644 aa
- Protein class
- Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Golgi apparatus
OverviewNCBI Gene
The protein encoded by this gene is a serine/threonine kinase and DNA damage sensor, activating cell cycle checkpoint signaling upon DNA stress. The encoded protein can phosphorylate and activate several proteins involved in the inhibition of DNA replication and mitosis, and can promote DNA repair, recombination, and apoptosis. This protein is also important for fragile site stability and centrosome duplication. Defects in this gene are a cause of Seckel syndrome 1. [provided by RefSeq, Aug 2017]
Canonical amino-acid sequenceUniProt
2644 residues, UniProt reviewed canonical sequence.
>Q13535|ATR
1 MGEHGLELAS MIPALRELGS ATPEEYNTVV QKPRQILCQF IDRILTDVNV VAVELVKKTD
61 SQPTSVMLLD FIQHIMKSSP LMFVNVSGSH EAKGSCIEFS NWIITRLLRI AATPSCHLLH
121 KKICEVICSL LFLFKSKSPA IFGVLTKELL QLFEDLVYLH RRNVMGHAVE WPVVMSRFLS
181 QLDEHMGYLQ SAPLQLMSMQ NLEFIEVTLL MVLTRIIAIV FFRRQELLLW QIGCVLLEYG
241 SPKIKSLAIS FLTELFQLGG LPAQPASTFF SSFLELLKHL VEMDTDQLKL YEEPLSKLIK
301 TLFPFEAEAY RNIEPVYLNM LLEKLCVMFE DGVLMRLKSD LLKAALCHLL QYFLKFVPAG
361 YESALQVRKV YVRNICKALL DVLGIEVDAE YLLGPLYAAL KMESMEIIEE IQCQTQQENL
421 SSNSDGISPK RRRLSSSLNP SKRAPKQTEE IKHVDMNQKS ILWSALKQKA ESLQISLEYS
481 GLKNPVIEML EGIAVVLQLT ALCTVHCSHQ NMNCRTFKDC QHKSKKKPSV VITWMSLDFY
541 TKVLKSCRSL LESVQKLDLE ATIDKVVKIY DALIYMQVNS SFEDHILEDL CGMLSLPWIY
601 SHSDDGCLKL TTFAANLLTL SCRISDSYSP QAQSRCVFLL TLFPRRIFLE WRTAVYNWAL
661 QSSHEVIRAS CVSGFFILLQ QQNSCNRVPK ILIDKVKDDS DIVKKEFASI LGQLVCTLHG
721 MFYLTSSLTE PFSEHGHVDL FCRNLKATSQ HECSSSQLKA SVCKPFLFLL KKKIPSPVKL
781 AFIDNLHHLC KHLDFREDET DVKAVLGTLL NLMEDPDKDV RVAFSGNIKH ILESLDSEDG
841 FIKELFVLRM KEAYTHAQIS RNNELKDTLI LTTGDIGRAA KGDLVPFALL HLLHCLLSKS
901 ASVSGAAYTE IRALVAAKSV KLQSFFSQYK KPICQFLVES LHSSQMTALP NTPCQNADVR
961 KQDVAHQREM ALNTLSEIAN VFDFPDLNRF LTRTLQVLLP DLAAKASPAA SALIRTLGKQ
1021 LNVNRREILI NNFKYIFSHL VCSCSKDELE RALHYLKNET EIELGSLLRQ DFQGLHNELL
1081 LRIGEHYQQV FNGLSILASF ASSDDPYQGP RDIISPELMA DYLQPKLLGI LAFFNMQLLS
1141 SSVGIEDKKM ALNSLMSLMK LMGPKHVSSV RVKMMTTLRT GLRFKDDFPE LCCRAWDCFV
1201 RCLDHACLGS LLSHVIVALL PLIHIQPKET AAIFHYLIIE NRDAVQDFLH EIYFLPDHPE
1261 LKKIKAVLQE YRKETSESTD LQTTLQLSMK AIQHENVDVR IHALTSLKET LYKNQEKLIK
1321 YATDSETVEP IISQLVTVLL KGCQDANSQA RLLCGECLGE LGAIDPGRLD FSTTETQGKD
1381 FTFVTGVEDS SFAYGLLMEL TRAYLAYADN SRAQDSAAYA IQELLSIYDC REMETNGPGH
1441 QLWRRFPEHV REILEPHLNT RYKSSQKSTD WSGVKKPIYL SKLGSNFAEW SASWAGYLIT
1501 KVRHDLASKI FTCCSIMMKH DFKVTIYLLP HILVYVLLGC NQEDQQEVYA EIMAVLKHDD
1561 QHTINTQDIA SDLCQLSTQT VFSMLDHLTQ WARHKFQALK AEKCPHSKSN RNKVDSMVST
1621 VDYEDYQSVT RFLDLIPQDT LAVASFRSKA YTRAVMHFES FITEKKQNIQ EHLGFLQKLY
1681 AAMHEPDGVA GVSAIRKAEP SLKEQILEHE SLGLLRDATA CYDRAIQLEP DQIIHYHGVV
1741 KSMLGLGQLS TVITQVNGVH ANRSEWTDEL NTYRVEAAWK LSQWDLVENY LAADGKSTTW
1801 SVRLGQLLLS AKKRDITAFY DSLKLVRAEQ IVPLSAASFE RGSYQRGYEY IVRLHMLCEL
1861 EHSIKPLFQH SPGDSSQEDS LNWVARLEMT QNSYRAKEPI LALRRALLSL NKRPDYNEMV
1921 GECWLQSARV ARKAGHHQTA YNALLNAGES RLAELYVERA KWLWSKGDVH QALIVLQKGV
1981 ELCFPENETP PEGKNMLIHG RAMLLVGRFM EETANFESNA IMKKYKDVTA CLPEWEDGHF
2041 YLAKYYDKLM PMVTDNKMEK QGDLIRYIVL HFGRSLQYGN QFIYQSMPRM LTLWLDYGTK
2101 AYEWEKAGRS DRVQMRNDLG KINKVITEHT NYLAPYQFLT AFSQLISRIC HSHDEVFVVL
2161 MEIIAKVFLA YPQQAMWMMT AVSKSSYPMR VNRCKEILNK AIHMKKSLEK FVGDATRLTD
2221 KLLELCNKPV DGSSSTLSMS THFKMLKKLV EEATFSEILI PLQSVMIPTL PSILGTHANH
2281 ASHEPFPGHW AYIAGFDDMV EILASLQKPK KISLKGSDGK FYIMMCKPKD DLRKDCRLME
2341 FNSLINKCLR KDAESRRREL HIRTYAVIPL NDECGIIEWV NNTAGLRPIL TKLYKEKGVY
2401 MTGKELRQCM LPKSAALSEK LKVFREFLLP RHPPIFHEWF LRTFPDPTSW YSSRSAYCRS
2461 TAVMSMVGYI LGLGDRHGEN ILFDSLTGEC VHVDFNCLFN KGETFEVPEI VPFRLTHNMV
2521 NGMGPMGTEG LFRRACEVTM RLMRDQREPL MSVLKTFLHD PLVEWSKPVK GHSKAPLNET
2581 GEVVNEKAKT HVLDIEQRLQ GVIKTRNRVT GLPLSIEGHV HYLIQEATDE NLLCQMYLGW
2641 TPYMLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ATR can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.25
- Highest tissue expression
- 4.9 nTPM
Expression across tissuesHPA
Tissue
- parathyroid gland: 4.9 nTPM
- testis: 4.9 nTPM
- thyroid gland: 4.8 nTPM
- adrenal gland: 4.6 nTPM
- thymus: 4.6 nTPM
- lymph node: 4.5 nTPM
Single-cell type
- adrenal cortex cells: 373 nCPM
- choroid plexus epithelial cells: 260 nCPM
- cone photoreceptor cells: 184 nCPM
- somatotrophs: 170 nCPM
- rod photoreceptor cells: 164 nCPM
- b-cells: 162 nCPM
Immune cell
- NK-cell: 1.4 nTPM
- MAIT T-cell: 1 nTPM
- myeloid DC: 0.7 nTPM
- gdT-cell: 0.5 nTPM
- memory CD8 T-cell: 0.5 nTPM
- intermediate monocyte: 0.4 nTPM
Brain region
- choroid plexus: 11 nTPM
- hypothalamus: 7.1 nTPM
- medulla oblongata: 6 nTPM
- cerebral cortex: 5.7 nTPM
- white matter: 5.7 nTPM
- pons: 5.6 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ATR.
Disease | AllUniProt
Conditions ATR is implicated in, by any mechanism.
- Seckel syndrome 1 (SCKL1) MIM:210600
- Cutaneous telangiectasia and cancer syndrome, familial (FCTCS) MIM:614564
Disease | GeneticClinVar
137 pathogenic / likely-pathogenic of 4,172 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Seckel syndrome 1
- Familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome
- Inborn genetic diseases
- ATR-related disorder
- Hereditary cancer-predisposing syndrome
Disease | ImmuneIEDB
Conditions an epitope on ATR was assayed in.
- melanoma T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.4
- gnomAD pLI
- 0
- gnomAD missense Z
- 4.36
- DepMap mean gene effect
- -1.35
- DepMap dependency class
- pan
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 11% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cellular response to gamma radiation
- cellular response to UV
- DNA damage checkpoint signaling
- DNA damage response
- DNA repair
- DNA replication
- double-strand break repair
- establishment of protein-containing complex localization to telomere
- establishment of RNA localization to telomere
- interstrand cross-link repair
- mitotic G2/M transition checkpoint
- negative regulation of DNA replication
- nuclear membrane disassembly
- nucleobase-containing compound metabolic process
- positive regulation of DNA damage response, signal transduction by p53 class mediator
- positive regulation of telomerase catalytic core complex assembly
- positive regulation of telomere maintenance via telomerase
- protein localization to chromosome, telomeric region
- regulation of cellular response to heat
- regulation of double-strand break repair
- replication fork processing
- replicative senescence
- response to arsenic-containing substance
- response to mechanical stimulus
- response to xenobiotic stimulus
- telomere maintenance
Molecular functions
- ATP binding
- DNA binding
- histone H2AXS139 kinase activity
- MutLalpha complex binding
- MutSalpha complex binding
- protein kinase activity
- protein serine kinase activity
- protein serine/threonine kinase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Phosphatidylinositol 3-/4-kinase, catalytic domain
- PIK-related kinase, FAT
- FATC domain
- Protein kinase-like domain superfamily
- Armadillo-like helical
- Tetratricopeptide-like helical domain superfamily
- PIK-related kinase, FAT domain
- Armadillo-type fold
- Phosphatidylinositol 3-/4-kinase, conserved site
- HEAT, type 2
- Phosphatidylinositol 3-/4-kinase, catalytic domain superfamily
- DNA Damage Response and Repair Kinase
- Serine/threonine-protein kinase ATR-like, HEAT repeats
- Phosphatidylinositol 3- and 4-kinase
- FAT domain
- FATC domain
- Serine/threonine-protein kinase ATR-like, HEAT repeats
- UME domain
- Serine/threonine-protein kinase ATR-like, M-HEAT region
- Serine/threonine-protein kinase ATR-like, N-HEAT region
- UME (NUC010) domain
- Serine/threonine-protein kinase ATR, M-HEAT region
- Serine/threonine-protein kinase ATR, N-HEAT region
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ATR in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ATR as an antibody target. Whether an autoantibody or antibody against ATR could matter depends on whether native ATR is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ATR is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ATR as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...